BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23359328)

  • 1. Reply: To PMID 22532296.
    Ferlitsch M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2013 Sep; 58(3):1189-90. PubMed ID: 23359328
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance of von willebrand factor in cirrhosis: a possible mechanism.
    Eapen CE; Elias JE; Mackie I; Elias E
    Hepatology; 2013 Sep; 58(3):1189. PubMed ID: 23348722
    [No Abstract]   [Full Text] [Related]  

  • 3. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score.
    Curakova Ristovska E; Genadieva-Dimitrova M; Caloska-Ivanova V; Misevski J
    Acta Gastroenterol Belg; 2019; 82(4):487-493. PubMed ID: 31950803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases.
    Nalpas B; Francoz C; Ichaï P; Jamot L; Faivre J; Lemoinne S; Samuel D; Durand F; Bernuau J; Bréchot C; Amouyal P; Amouyal G
    Gut; 2012 Jul; 61(7):1098-100. PubMed ID: 22027480
    [No Abstract]   [Full Text] [Related]  

  • 6. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
    Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
    Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
    PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble P selectin levels in chronic liver disease: relationship to disease severity.
    Vardareli E; Saricam T; Demirustu C; Gulbas Z
    Hepatogastroenterology; 2007 Mar; 54(74):466-9. PubMed ID: 17523300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.
    Kalambokis GN; Baltayiannis G; Christodoulou D
    World J Gastroenterol; 2016 May; 22(19):4786-8. PubMed ID: 27217711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognosis of liver failure in patients with liver cirrhosis under surgical treatment for portal hypertension].
    Beresnev AV; Siplivyĭ VA; Mel'nikova SM; Cherevatova SKh
    Klin Khir (1962); 1993; (11):38-40. PubMed ID: 8207909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis.
    Lim YL; Choi E; Jang YO; Cho YZ; Kang YS; Baik SK; Kwon SO; Kim MY
    Gut Liver; 2016 Jan; 10(1):109-16. PubMed ID: 25963087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis-Authors' reply.
    Mandorfer M; Reiberger T; Ferlitsch A;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1537-1538. PubMed ID: 29878416
    [No Abstract]   [Full Text] [Related]  

  • 15. Estrogens and portal hypertension in cirrhosis of the liver.
    Gluud C; Henriksen HH; Svenstrup B
    N Engl J Med; 1981 Jan; 304(1):52. PubMed ID: 7432439
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma angiotensin activity in cirrhosis of the liver and idiopathic portal hypertension.
    Dass BK; Chaudhury RR; Chhuttani PN; Saini VK; Datta DV
    Indian J Med Res; 1976 Mar; 64(3):418-24. PubMed ID: 965044
    [No Abstract]   [Full Text] [Related]  

  • 17. [Circulation in liver cirrhosis patients and the principles for correcting portal hypertension].
    Patsiora MD; Ershov IuA
    Khirurgiia (Mosk); 1973 May; 49(5):72-9. PubMed ID: 4795477
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum haptoglobins in hepatic cirrhosis with portal hypertension and secondary hypersplenism].
    Vai C; Santese R; Andreuzzi B; Gelosa F; Rotondo F
    Minerva Dietol Gastroenterol; 1983; 29(4):313-6. PubMed ID: 6672672
    [No Abstract]   [Full Text] [Related]  

  • 19. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
    Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of the cytopenia syndrome in patients with cirrhosis of the liver complicated by portal hypertension].
    Eramishantsev AK; Korshunov IB; Belokrinitskiĭ DV; Dudkina LN; Dem'ianov AI
    Khirurgiia (Mosk); 1989 Feb; (2):36-9. PubMed ID: 2709711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.